These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 21558879)

  • 1. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Ta NN; Schuyler CA; Li Y; Lopes-Virella MF; Huang Y
    J Cardiovasc Pharmacol; 2011 Aug; 58(2):157-66. PubMed ID: 21558879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
    Shah Z; Kampfrath T; Deiuliis JA; Zhong J; Pineda C; Ying Z; Xu X; Lu B; Moffatt-Bruce S; Durairaj R; Sun Q; Mihai G; Maiseyeu A; Rajagopalan S
    Circulation; 2011 Nov; 124(21):2338-49. PubMed ID: 22007077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.
    Ta NN; Li Y; Schuyler CA; Lopes-Virella MF; Huang Y
    Atherosclerosis; 2010 Dec; 213(2):429-35. PubMed ID: 20843518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice.
    Akita K; Isoda K; Shimada K; Daida H
    J Am Heart Assoc; 2015 Mar; 4(3):e001469. PubMed ID: 25770025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model.
    Yisireyili M; Takeshita K; Hayashi M; Wu H; Uchida Y; Yamamoto K; Kikuchi R; Hao CN; Nakayama T; Cheng XW; Matsushita T; Nakamura S; Murohara T
    Psychoneuroendocrinology; 2016 Nov; 73():186-195. PubMed ID: 27509090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
    Terasaki M; Nagashima M; Nohtomi K; Kohashi K; Tomoyasu M; Sinmura K; Nogi Y; Katayama Y; Sato K; Itoh F; Watanabe T; Hirano T
    PLoS One; 2013; 8(8):e70933. PubMed ID: 23967137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.
    Kusunoki M; Sato D; Nakamura T; Oshida Y; Tsutsui H; Natsume Y; Tsutsumi K; Miyata T
    Drug Res (Stuttg); 2016 Jan; 66(1):18-22. PubMed ID: 26125284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
    Mita T; Katakami N; Yoshii H; Onuma T; Kaneto H; Osonoi T; Shiraiwa T; Kosugi K; Umayahara Y; Yamamoto T; Yokoyama H; Kuribayashi N; Jinnouchi H; Gosho M; Shimomura I; Watada H;
    Diabetes Care; 2016 Jan; 39(1):139-48. PubMed ID: 26628419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
    Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
    Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Vascul Pharmacol; 2017 Sep; 96-98():19-25. PubMed ID: 28347868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
    Katakami N; Mita T; Yoshii H; Onuma T; Kaneto H; Osonoi T; Shiraiwa T; Kosugi K; Umayahara Y; Yamamoto T; Yokoyama H; Kuribayashi N; Jinnouchi H; Gosho M; Watada H; Shimomura I;
    J Atheroscler Thromb; 2013; 20(12):893-902. PubMed ID: 23965491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
    Said S; Nwosu AC; Mukherjee D; Hernandez GT
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
    Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
    Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alogliptin benzoate for the treatment of type 2 diabetes.
    Rendell M; Drincic A; Andukuri R
    Expert Opin Pharmacother; 2012 Mar; 13(4):553-63. PubMed ID: 22296609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
    Agrawal R; Bahare RS; Jain P; Dikshit SN; Ganguly S
    Mini Rev Med Chem; 2012 Nov; 12(13):1345-58. PubMed ID: 22512582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alogliptin benzoate for management of type 2 diabetes.
    Saisho Y
    Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin.
    Lai ZW; Li C; Liu J; Kong L; Wen X; Sun H
    Eur J Med Chem; 2014 Aug; 83():547-60. PubMed ID: 24996141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.